Focal Point Ireland: national report for 2017. by unknown
1 
 
 
Focal Point Ireland: national 
report for 2017 - harms and harm 
reduction  
Health Research Board. Irish Focal Point to the European Monitoring Centre for Drugs and 
Drug Addiction 
 
 
 
Authors of the national report 
Lucy Dillon, Brian Galvin, Ciara Guiney, Suzi Lyons, and Sean Millar 
 
Head of Irish Focal Point 
Brian Galvin 
 
All of the documents used in the preparation of the national report are available on the HRB 
National Drugs Library’s repository at www.drugsandalcohol.ie.  
 
This document was prepared for publication by the staff of the HRB National Drugs Library 
 
 
 
Please use the following citation: 
Health Research Board. Irish National Focal Point to the European Monitoring Centre for Drugs and 
Drug Addiction (2018) Focal Point Ireland: national report for 2017 – harms and harm 
reduction. Dublin: Health Research Board. 
 
 
Other reports in this National report series can be found at 
http://www.drugsandalcohol.ie/php/annual_report.php  
 
(2018) Focal Point Ireland: national report for 2017 – drug policy.  
(2018) Focal Point Ireland: national report for 2017 – treatment.  
(2018) Focal Point Ireland: national report for 2017 – drug markets and crime.  
(2018) Focal Point Ireland: national report for 2017 – prevention.  
(2018) Focal Point Ireland: national report for 2017 – legal framework.  
(2018) Focal Point Ireland: national report for 2017 – prison. 
(2018) Focal Point Ireland: national report for 2017 – drugs. 
 
                                              
2 
 
Table of Contents 
1. National profile ............................................................................................................................ 3 
1.1 Drug-related deaths .............................................................................................................................. 3 
1.1.1 Overdose deaths .............................................................................................................................. 3 
1.1.2 Toxicology of overdose deaths ...................................................................................................... 4 
1.1.3 Mortality cohort studies ................................................................................................................... 4 
1.1.4 Trends ................................................................................................................................................ 4 
1.1.5 Additional information on drug-related deaths............................................................................. 5 
1.2 Drug related acute emergencies ....................................................................................................... 6 
1.2.1 Drug-related acute emergencies ................................................................................................... 6 
1.2.2 Toxicology of drug-related acute emergencies ........................................................................... 8 
1.2.4 Additional information on drug-related acute emergencies .....................................................10 
1.3 Drug related infectious diseases ....................................................................................................12 
1.3.1 Main drug-related infectious diseases among drug users – HIV, HBV, HCV .......................12 
1.3.2 Notification of drug-related infectious diseases.........................................................................16 
1.3.3 Prevalence data of drug-related infectious diseases outside the routine monitoring ..........17 
1.3.4 Additional information on drug-related infectious diseases .....................................................20 
1.4 Other drug-related health harms ....................................................................................................22 
1.4.1 Other drug-related health harms .................................................................................................22 
1.5 Harm reduction interventions ..........................................................................................................24 
1.5.1 Drug policy and main harm reduction objectives ......................................................................24 
1.5.2 Organisation of harm reduction services ....................................................................................25 
1.5.3 Harm reduction services ...............................................................................................................25 
1.5.4 Harm reduction services: availability and access .....................................................................36 
2. New developments ................................................................................................................... 38 
2.1 New developments in drug-related infectious diseases ..................................................................38 
2.2 New developments in harm reduction interventions ........................................................................39 
3. Additional information .............................................................................................................. 40 
3.1 Additional sources of information........................................................................................................40 
4. Sources and methodology ....................................................................................................... 41 
4.1 Sources ...............................................................................................................................................41 
4.2 Methodology .......................................................................................................................................41 
4.2 References .........................................................................................................................................42 
Acknowledgements ...................................................................................................................... 44 
 
 
 
3 
 
0. Summary 
Ireland maintains a special register that is a complete census of all drug-induced deaths in the 
country. Established in 2005, the National Drug-Related Deaths Index (NDRDI), which is maintained 
by the Health Research Board (HRB), is an epidemiological database that records cases of death 
by drugs poisoning, as well as deaths among drug users in Ireland, extending back to 1998.  
 
Data on drug-related acute emergencies in the Irish context refer to all admissions to acute general 
hospitals with non-fatal overdoses and are extracted from the Hospital In-Patient Enquiry (HIPE) 
scheme.  
 
Newly diagnosed cases of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) are reported to 
the Health Protection Surveillance Centre (HPSC). Notification data for 2016 are included in this 
workbook. 
 
The number of drug-induced deaths remained stable in 2015, at 224, compared to 223 deaths in 
2014.  The majority of those who died were male, aged in their thirties.  Opiates were the most 
common drug associated with most drug-induced deaths as per the EMCDDA Filter D inclusion 
criteria.   
 
The number of overdose cases admitted to Irish hospitals decreased from 4,256 in 2014. Trends 
over time show a general decrease in overdose cases, falling from 5,012 cases in 2005 to 3,956 
cases in 2015. 
 
Recent trends indicate that the number of cases of HBV and HCV diagnosed and reported in the 
Republic of Ireland is stabilising rather than continuing to decline. There has also been an overall 
increase in the number of reported HIV cases; the increased number of people who inject drugs 
(PWID) among HIV cases reported since 2014 was due to an outbreak of HIV among homeless 
drug users in Dublin. 
 
Harm reduction services available in Ireland include needle exchanges from fixed sites, mobile units 
and outreach work provided by regional authorities and community-based organisations. In addition, 
there are pharmacies providing needle exchanges in each local and regional drug and alcohol task 
force (RDTF) area within Ireland apart from those covering counties Dublin, Kildare and Wicklow. At 
the end of 2016, there were 111 pharmacies providing needle exchanges, and an average of 1,614 
individuals used pharmacy needle exchanges each month in 2016.  
 
 
1. National profile 
1.1 Drug-related deaths  
1.1.1 Overdose deaths 
In 2015, there were 224 deaths owing to poisoning recorded in Ireland by the National Drug-Related 
Deaths Index (NDRDI) as per Selection D (also see ST 5 and ST 6). The number of deaths owing to 
poisoning over the past three years appear to have stabilisation in Ireland, with 223 deaths reported 
in 2014. It should be noted that annual data previously reported have been changed as the NDRDI 
figures have been updated as new information has become available.   
 
Overall, the mean age of those who died (39 years) in 2015 owing to poisoning remained stable 
(39.1 years) compared to 2014 (35.2 years). The mean age is the highest recorded, driven by the 
increase in deaths in those aged 55 years and older (24, 11.0%) compared to 2014 (5, 2.2%). The 
reason for this increase is not yet known although 58% were female. 
 
The majority of deaths were male (64.3%) similar to previous years. The NDRDI does not routinely 
report the intentionality of the death. 
 
The overall trends in overdose deaths for the EMCDDA definition of Filter D remain the same, with 
opiates continuing to be associated with most poisoning deaths as opiates were found in 94% of 
cases who had a toxicology available (see Section 1.1.2 below).  
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Due to circumstances beyond the control of the Focal Point more in-depth analysis of the 2015 data 
is not possible at this juncture in time. 
 
1.1.2 Toxicology of overdose deaths 
Toxicology was available for 202 deaths in 2015 (also see ST5). Not all deaths reported in Filter D 
have a toxicology result. Opiates were found in the post-mortem toxicology of 95% (192/202) of 
these deaths. Due to circumstances beyond the control of the Focal Point more in-depth analysis of 
the 2015 data is not possible at this juncture in time. 
 
1.1.3 Mortality cohort studies 
There are no mortality cohort studies to report for 2016. 
 
1.1.4 Trends 
The number of DRD in Ireland has increased from 187 deaths in 2006 to 224 in 2015 (also see 
Standard Table 6). The numbers have fluctuated over the period, with a dip in 2010 but have been 
relatively stable since 2013.  
 
The majority of deaths involve opiates. This is not surprising given the high prevalence of problem 
opiate use in Ireland (see TDI and Treatment workbook). The majority of opiate deaths involve 
heroin and methadone (either prescribed or street) or a combination of both (Health Research 
Board 2016). Up to 2010, more deaths involved heroin, but since then more deaths have involved 
methadone (as of 2014, the most recent year available). There has as yet been no analysis of why 
the numbers of methadone-related deaths have increased. The number of clients in opioid 
substitution treatment (OST) has increased steadily over the same period however studies have 
shown that retention in treatment has a protective effect (Cousins, et al. 2017, Cousins, et al. 2016). 
There was a recorded heroin drought in Ireland around 2010 (O'Keefe 2010, December 16) (Attewill 
2011, 31 January) and this may have had some impact on this change.   
 
Another significant factor in DRD has been the increase of polydrug deaths. In 2014 (the most 
recent year of data available), the majority of poisoning deaths (182, 85.0%) involved more than one 
drug. The majority (163/182, 89.6%) of polydrug poisoning deaths involved opiates. The most 
common other additional drugs involved were benzodiazepines, alcohol, antidepressants, and other 
prescriptions medications. The proportion of heroin-related deaths where polydrugs were implicated 
has risen from 60% in 2006 to 81% in 2014 (the most recent year data is available) (Health 
Research Board 2016).  
 
Injecting is a significant factor for heroin-related deaths. In 2014 (the most recent year of data 
available), 48% of those who died where heroin was implicated were known to be injecting. 
However this has reduced from 65% in 2006. Nearly half (47%) of those who died while injecting 
heroin were in a private dwelling. Twenty-nine per cent of these who died because of heroin were 
homeless in 2014 (Health Research Board 2016). A naloxone demonstration project was conducted 
in 2015 (See T.1.5.3 below) which utilised NDRDI data to inform the methodology. The NDRDI will 
also be able to evaluate the effectiveness of the programme in reducing DRD in Ireland in the 
coming years. 
 
Due to circumstances beyond the control of the Focal Point, a more in-depth analysis of the 2015 
data is not possible at this time. 
 
 
Data completeness/coverage; case ascertainment, changes in reporting 
The NDRDI, the Irish Special Register for DRD has been in existence since 2007 utilising Filter D as 
a selector. Up to that point, DRD were reported through the GMR. However the NDRDI 
retrospectively collected data back to 1998. Therefore the NDRDI data supersedes any data 
previously reported between 1998 and 2007.  
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The NDRDI is a complete census of all drug-related deaths in Ireland, both direct drug deaths 
through overdose (known as poisoning) and deaths among drug users. Of note, it also collects 
additional deaths which do not meet the Filter D criteria but are of national importance, e.g. alcohol 
only and alcohol in combination with prescription drug overdose/poisonings deaths. The NDRDI is a 
national census as it collects information from all closed Coronial files, all deaths among hospital 
inpatients which meet the criteria, all deaths among those registered on OST and the general 
mortality registry (GMR). All of data these sources are matched to avoid duplication and to insure 
the greatest amount of information on each death. There has been no change in the process since 
the inception of the NDRDI. 
 
1.1.5 Additional information on drug-related deaths 
Overview of all drug-related deaths (including alcohol) in Ireland, 2014 
The annual overview of all drug-related deaths in Ireland for 2014 showed that alcohol continued to 
be the drug most commonly implicated in poisonings deaths (Health Research Board 2016). This 
overview includes both illicit drugs (covered by Section D and reported through ST5 & 6) in addition 
to other drugs such as alcohol and prescription medication not reported in ST5 & 6. It also includes 
data on non-poisoning deaths among drug users.1 
 
The latest figures from the NDRDI show that a total of 697 deaths in Ireland during 2014 were linked 
to drug use. The NDRDI reports on poisoning deaths (also known as overdose), which are due to 
the toxic effect of a drug or combination of drugs, and on non-poisonings, which are deaths among 
people who use drugs as a result of trauma such as hanging, or medical reasons such as cardiac 
events. 
 
In the eleven-year period from 2004 to 2014 inclusive, a total of 6,697 deaths by drug poisoning and 
deaths among drug users met the criteria for inclusion in the NDRDI database. Of these deaths, 
3,864 (58%) were due to poisoning and 2,833 (42%) were deaths among drug users (non-
poisoning) (Table 1.1.5.1). There were 697 deaths in 2014, similar to the number reported in 2013 
(698). 
 
Many of these deaths were premature, with half of all deaths in 2014 aged 39 years or younger. 
Three in four (523) of all deaths in 2014 were male. 
 
Some of the key findings of the report include the following: 
 Prescription drugs were implicated in 259 (three in every four) poisonings during 2014. 
 Two hundred and thirty-five people died in 2014 because they took a mixture of drugs, with 
an average of four drugs involved. 
 Benzodiazepines were the most common drug group involved in polydrug deaths. 
 Notwithstanding a small decrease in alcohol poisonings, alcohol is still implicated in one-in-
three deaths and remains the single most common drug implicated in deaths over the 
reporting period 2004‒2014.  
 Opiates were the main drug group implicated in poisonings. 
 Hanging was the main cause of non-poisoning deaths. There was a 21% increase in deaths 
due to hanging between 2013 and 2014.  
 
Table 1.1.5.1 Number of deaths, by year, NDRDI 2004‒2014 (N=6697) 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
All deaths 431 503 554 620 628 656 607 643 660 698 697 
Poisonings (3864) 266 301 326 387 386 372 340 377 358 397 354 
Non-poisonings (2833) 165 202 228 233 242 284 267 266 302 301 343 
Source: NDRDI, 2017 
Poisoning deaths in 2014 
                                                          
1
 This annual overview is published only after DRD data is reported to the EMCDDA.  Therefore the report reproduced 
here refers to 2013 data which was not published at the time the previous workbook was compiled.  The national overview 
for 2015 is not yet published so cannot be included in this workbook 
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The annual number of poisoning deaths decreased by 11%, from 397 in 2013 to 354 in 2014 (Table 
1.1.5.1). As in previous years, the majority (72%) were male. The median age of those who died 
was 39 years, again similar to previous years.  
 
Prescription drugs were implicated in 259 (three in every four) poisoning deaths. With regard to 
prescription drugs: 
 
 Benzodiazepines were the most common prescription drug group implicated. 
 Diazepam (a benzodiazepine) was the most common single prescription drug, implicated in 
115 (32%) of all poisoning deaths. 
 Methadone was implicated in more than a quarter of poisonings (n=98, 28%). 
 Zopiclone-related deaths (a non-benzodiazepine sedative drug) increased by 41% from 51 in 
2013 to 72 in 2014. 
 
Alcohol continues to be the single most common drug implicated over the reporting period. Alcohol 
was implicated in one-in-three of all poisonings, and alcohol alone was responsible for 13% of all 
poisoning deaths. 
 
The number of deaths where illicit drugs were implicated increased. Of particular note: 
 Heroin was implicated in one-in-four (n=90) deaths and 42% of these people were not alone 
at the time of the incident that led to their deaths. 
 Cocaine-related deaths increased by 25% from 32 in 2013 to 40 in 2014. 
 MDMA-related deaths continue to increase from less than 5 in 2010 to 15 in 2014. 
 
Polydrug use is a significant risk factor for fatal overdose. In 2004, 44% or 118 deaths were due to a 
cocktail of drugs, with an average of two drugs taken. In 2014, this had risen to 66% or 235 deaths, 
with an average of four different drugs taken. Regarding polydrug use: 
 59% of deaths where alcohol was implicated involved other drugs, mainly opiates. 
 92% of deaths where methadone was implicated involved other drugs, mainly 
benzodiazepines. 
 81% of deaths where heroin was implicated involved other drugs, mainly benzodiazepines. 
 Almost all deaths (98%) where cocaine was implicated involved other drugs. 
 
Non-poisoning deaths in 2014 
The number of non-poisoning deaths increased by 14%, from 301 in 2013 to 343 in 2014. (Table 
1.1.5.1.). Non-poisoning deaths are categorised as being due to either trauma (n=177) or medical 
causes (n=116). 
The main causes of non-poisoning deaths were hanging (27%) and cardiac events (15%). There 
was a 21% increase in deaths due to hanging between 2013 and 2014. More than two-thirds (67%) 
of people who died as a result of hanging had a history of mental health illness. 
1.2 Drug related acute emergencies 
1.2.1 Drug-related acute emergencies 
Monitoring of drug-related acute emergencies in the Irish context refers to all admissions for non-
fatal overdoses to acute general hospitals in Ireland. A description of the main monitoring systems 
and sources of data are included at the end of this workbook. 
 
Drug-related emergencies – non-fatal overdoses  
Data extracted from the Hospital In-Patient Enquiry (HIPE) scheme were analysed to determine 
trends in non-fatal overdoses in patients discharged from Irish hospitals in 2015. In total, there were 
4,023 overdose cases in that year. Of those cases, 67 died in hospital; only discharged cases are 
included in this analysis. The number of overdose cases in 2015 decreased from 4,256 cases in 
2014, and trends over time indicate a general decrease in overdose cases admitted to Irish 
hospitals, falling from 5,012 cases in 2005 to 3,956 cases in 2015 (Figure 1.2.1.1). 
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Figure 1.2.1.1 Number of non-fatal overdose cases admitted to Irish hospitals by year, 2005–2015  
Source: HIPE, Healthcare Pricing Office, 2017 
 
 
Gender 
Between 2005 and 2015, there were more overdose cases among women than among men, with 
women accounting for 2,288 (58%) of all non-fatal overdose cases in 2015 (Figure 1.2.1.2). 
 
Figure 1.2.1.2 Number of non-fatal overdose cases admitted to Irish hospitals, by year and gender, 2005–2015 
Source: HIPE, Healthcare Pricing Office, 2017 
 
 
Age group 
Between 2014 and 2015, there was a decrease in the number of non-fatal overdose cases among 
those aged 15 to 34 and in all age groups from 45 to 74 years. As noted in previous annual reports, 
the incidence of overdose cases peaks in the 15-24 age group, and thereafter decreases with age 
(Figure 1.2.1.3). Trends over time show that in 2005, 40% of cases involved patients younger than 
25 years of age; the comparable figure in 2015 was 32%. 
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Figure 1.2.1.3 Non-fatal overdose cases admitted to Irish hospitals, by year and age group, 2010–2015 
Source: HIPE, Healthcare Pricing Office, 2017 
1.2.2 Toxicology of drug-related acute emergencies 
Drugs involved 
Table 1.2.2.1 presents the positive test results per category of drugs and other substances involved 
in all overdose cases in 2015. 
 
Non-opioid analgesics were present in 35% (1,393) of cases. Paracetamol is included in this drug 
category and was present in 28% (1,118) of cases. Psychotropic agents were taken in 25% (986) of 
cases and benzodiazepines in 18% (716) of cases. There was evidence of alcohol consumption in 
8% (331) of cases. Cases involving alcohol are included in this analysis only when alcohol was used 
in conjunction with another substance. 
 
Table 1.2.2.1 Categories of drugs involved in non-fatal overdose cases admitted to Irish hospitals, 2015 (n=3,956)*  
Drug category Number % 
Non-opioid analgesics 1,393 35.2 
Paracetamol (4-Aminophenol derivatives) 1118 28.3 
Benzodiazepines 716 18.0 
Psychotropic agents 986 24.9 
Anti-epileptic/sedative/anti-Parkinson agents 1795 45.3 
Narcotics and hallucinogens 662 16.7 
Alcohol 331 8.4 
Systemic and haematological agents 140 3.5 
Cardiovascular agents 141 3.5 
Autonomic nervous system 124 3.1 
Anaesthetics 14 0.3 
Hormones 116 2.9 
Systemic antibiotics 65 1.6 
Gastrointestinal agents 71 1.8 
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Drug category Number % 
Other chemicals and noxious substance 280 7.0 
Diuretics 54 1.4 
Muscle and respiratory agents 27 0.6 
Topical agents 35 0.8 
Anti-infectives/anti-parasitics 18 0.4 
Other gases and vapours 58 1.5 
Other and unspecified drugs 790 20.0 
Source: HIPE, Healthcare Pricing Office, 2017 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one drug or substance. 
 
 
Overdoses involving narcotics or hallucinogens 
Figure 1.2.2.1 shows the number of positive test results for illicit substances among overdose cases 
in 2015. Opiates were used in 13% (528) of cases, cocaine in 2.4% (96) and cannabis in 1.6% (64) 
of cases. There were no overdose cases involving hallucinogenic substances. 
 
 
Figure 1.2.2.1 Narcotics and hallucinogens involved in overdose cases admitted to Irish hospitals, 2015  
Source: HIPE, Healthcare Pricing Office, 2017 
 
Overdoses classified by intent 
In 63% (2,490) of cases in 2015, the overdose was classified as intentional (Figure 1.2.2.2). In 410 
cases, the intent was not clear; these cases were not included in the analysis. 
 
 
Figure 1.2.2.2 Overdose cases admitted to Irish hospitals, classified by intent, 2015 
Source: HIPE, Healthcare Pricing Office, 2017 
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Table 1.2.2.2 the number of positive test results per category of drugs and other substances 
involved in cases of intentional self-poisoning (n=2,490) in 2015. Non-opioid analgesics were 
involved in 44% (1,098) of cases, benzodiazepines in 21% (532) and psychotropic agents in 30% 
(748) of cases. 
 
Table 1.2.2.2 Categories of drugs involved in intentional self-poisoning cases admitted to Irish hospitals, 2015 
(n=2,490)* 
Drug category Number % 
Non-opioid analgesics 1098 44.0 
Benzodiazepines 532 21.4 
Psychotropic agents 748 30.0 
Anti-epileptic/sedative/anti-Parkinson agents 1331 43.5 
Narcotics and hallucinogens 360 14.5 
Alcohol
**
 248 10.0 
Systemic and haematological agents 63 1.4 
Cardiovascular agents 82 3.3 
Autonomic nervous system 84 3.4 
Anaesthetics ~ ~ 
Hormones 75 3.0 
Systemic antibiotics 45 1.8 
Gastrointestinal agents 48 1.9 
Other chemicals and noxious substance 102 4.1 
Diuretics 31 1.2 
Muscle and respiratory agents 14 0.6 
Topical agents 9 0.4 
Anti-infectives/anti-parasitics 14 0.6 
Other gases and vapours 7 0.3 
Other and unspecified drugs 427 1.7 
Source: HIPE, Healthcare Pricing Office, 2017 
* Some discharges may be included in more than one drug category; therefore, the total count in this table exceeds the total number of 
discharges. 
** Alcohol was only included for cases where any code from any of the other drug categories in this table was also reported. 
~ denotes five or fewer discharges reported to HIPE. 
 
1.2.4 Additional information on drug-related acute emergencies 
 
Drug admissions to psychiatric facilities 
Drug and alcohol admissions to psychiatric facilities 
Data from Activities of Irish Psychiatric Units and Hospitals 2015, the annual report published by the 
Mental Health Information Systems Unit of the HRB, has shown that the total number of first 
admissions to inpatient care for persons with an alcohol disorder has continued to fall (Daly and 
Craig 2016). 
 
In 2015, 1,188 cases with an alcohol disorder were admitted to psychiatric facilities, of whom 437 
were treated for the first time. Figure 1.2.4.1 presents the rates of first admission between 1995 and 
2015. The overall trend observed since 1995 has continued, with a reduction in the rate of first 
admissions in 2015 compared to 2014. Slightly more than 33% of all cases hospitalised for an 
alcohol disorder in 2015 stayed for just under one week, and 28% of cases were hospitalised for 
between one and three months.   
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Figure 1.2.4.1 Rates of psychiatric first admission of cases with a diagnosis of an alcohol disorder per 100,000 of 
the population in Ireland, 1995 to 2015  
Source: Daly and Craig, 2016 
 
However, trends of first admissions for an alcohol disorder contrast with those observed for patients 
with a drug disorder. Figure 1.2.4.2 presents the rates of first admission between 1995 and 2015 for 
drug disorder cases. In 2015, 1,032 persons were admitted to psychiatric facilities with a drug 
disorder. Of these cases, 448 were treated for the first time, which represents a rate of 9.8 per 
100,000 of the population, the highest rate recorded since 1995. Since 2006 there has been a 
general increase in the rate of first admissions. It should be noted, however, that the report does not 
present data on drug use and psychiatric co-morbidity, so it is not possible to determine whether or 
not these admissions were appropriate.   
 
  
Figure 1.2.4.2 Rates of psychiatric first admission of cases with a diagnosis of a drug disorder per 100,000 of the 
population in Ireland, 1995–2015 
Source: Daly and Craig, 2016  
 
Other notable statistics on admissions for a drug disorder in 2015 include the following: 
 
 Just under half (47.1%) of cases hospitalised for a drug disorder stayed for less than one 
week, and 98% were discharged within three months. It should be noted that admissions 
and discharges represent individual episodes or events and not persons. 
 Eleven per cent of first-time admissions were involuntary. 
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 The rate of first-time admissions was higher for men (14.2 per 100,000 of the population) 
than for women (5.4 per 100,000 of the population). 
 
The overall increase in the rate of drug-related first admissions between 1995 and 2015 may reflect 
an overall increase in problem drug use in Ireland and its increasing burden on psychiatric and 
mental-health services.  
 
 
1.3 Drug related infectious diseases 
1.3.1 Main drug-related infectious diseases among drug users – HIV, HBV, HCV 
 
New HIV notifications, 2016 
According to data compiled by the Health Protection Surveillance Centre (HPSC), at the end of 
2016, 512 people were newly diagnosed with HIV in Ireland, a notification rate of 11.2 per 100,000 
population. This marks an increase of almost 6% compared to 2015, with 485 new HIV diagnoses 
(Figure 1.3.1.1). 
 
The increased number of recent HIV infection among PWID is being investigated and may be partly 
explained by the changes in reporting procedures in HSE East. In addition, there was an outbreak in 
Dublin among PWID in 2014/15. A detailed review of the region of origin, mode of transmission, 
duration of drug use and co-infection is also being conducted. 
 
 
Figure 1.3.1.1 Number of new HIV notifications reported in Ireland, by year of notification, 2003–2016 
Source: Health Service Executive (HSE) and HPSC, 2017  
 
 
Of the new HIV notifications in 2016: 
 
 394 were male and 118 were female; 
 266 were born outside Ireland; 
 141 had previously been diagnosed HIV-positive in another country; 
 237 were men who have sex with men; 
 96 were classified as ‘other’ (including mother-to-child transmission); and 
 for 31% (160) of new HIV notifications in 2016, there was no reported risk factor, although 
this is likely to change as more data become available. 
 
In 2016, 19 new HIV notifications were people who inject drugs (PWID) (Table 1.3.1.1). This 
compares with 45 notifications in 2015. The figure for 2015 was the highest number of PWID among 
HIV notifications since 2008 (Figure 1.3.1.2). 
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Table 1.3.1.1 New HIV notifications reported to the HPSC by risk factor status, 2016 
Risk factor status n (%) 
Total   512 
  
Cases with reported risk factor data   352 (68.8)  
Of which:  
Injecting drug users  19 (5.4) 
Men who have sex with men  237 (67.3) 
Recipient blood/blood products  0 (0) 
Other risk factors  96 (27.3) 
No known risk factor identified  0 (0) 
  
Cases without reported risk factor data  160 (31.3) 
Source: HSE and HPSC, 2017 
 
 
Figure 1.3.1.2 Number and rolling average number of PWID among HIV notifications reported in Ireland, by year of 
notification, 2003–2016 
Source: HSE and HPSC, 2017 
 
 
Of the PWID among new HIV notifications in 2016, 13 were male and six were female, with a 
median age of 35. Two subjects were under 25 years of age. The majority (84%) resided in Dublin, 
Kildare or Wicklow (Table 1.3.1.2). 
 
Table 1.3.1.2 Characteristics of new HIV notifications who reported injecting drug use as a risk factor, 2016 
Known injector cases  n (%) 
Total   19 
  
Gender  
Male  13 (68.4) 
Female  6 (31.6) 
Gender unknown  0 (0) 
  
Age  
Mean age  36.2 
Median age  35 
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Known injector cases  n (%) 
Under 25 years  2 (10.5) 
25-34 years  6 (31.6) 
Age unknown  0 
  
Place of residence   
Dublin, Kildare or Wicklow  16 (84.2) 
Elsewhere in Ireland  3 (15.8) 
Source: HSE and HPSC, 2017 
 
The increased number of PWID among new HIV notifications in 2014/15 was due to an outbreak of 
HIV among homeless drug users in Dublin; see the 2016 National Report, Section 1.3.6. 
 
HBV notifications, 2016 
There were 488 notifications of HBV in 2016, a decrease of 11% from 2015, when there were 548 
notifications. The notification rate for 2016 was 10.2 per 100,000 population. HBV notifications 
halved between 2008 (n=899, 21.2/100,000 population) and 2014 (n=442, 9.3/100,000 population), 
but recent trends suggest that the number of cases diagnosed and notified is stabilising rather than 
continuing to decline (Figure 1.3.1.3).   
 
 
Figure 1.3.1.3 Number of HBV notifications reported in Ireland, by year of notification, 2004–2016 
Source: HSE and HPSC, 2017  
 
Ninety-three per cent (n=452) of the 488 new HBV notifications in 2016 contained information on 
acute/chronic status. Of these, 93% (n=420) were chronically infected (long-term infection) and 7% 
(n=32) were acutely infected (recent infection). 
 
Seventy-eight per cent (n=25) of known acute cases in 2016 were male. Cases ranged in age from 
26 to 69 years. The overall median age at notification was 36 years. Male cases were older on 
average, with a median age at notification of 37 years compared to 28 years for female cases. 
 
Risk factor data were available for 81% (n=26) of the acute cases notified in 2016. Of these, 65% 
(n=17) were likely to have been sexually acquired (10 were heterosexual, seven were men who 
have sex with men). One notification was an injecting drug user (Table 1.3.1.3). A further two cases 
reported possible blood exposure when snorting cocaine. 
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Table 1.3.1.3 Acute and chronic new HBV cases reported to the HPSC, 2016 
HBV status Acute  Chronic  Unknown  
  n (%) n (%) n (%) 
       
Total number of cases 32 420 36 
Percentage of cases by status (6.6) (86.1) (7.4) 
        
Cases with reported risk factor data 26 79 3 
Percentage of cases with risk factor data (81.3) (18.8) (8.3) 
Of which:       
Injecting drug users 1 (3.8) 3 (3.8) 0 (0) 
        
Cases without reported risk factor data 6 341 33 
Percentage of cases without risk factor data (18.8) (81.2) (91.7) 
Source: HSE and HPSC, 2017  
Two additional cases had a risk factor of snorting cocaine but were not PWID.      
Two acute cases that did not have primary risk factor data reported that they were born in an endemic country or were asylum seekers. 
 
 
New HCV notifications, 2016 
There were 645 new HCV notifications in the Republic of Ireland in 2016, a decrease of 4% from 
2015, when there were 675 notifications. The notification rate for 2016 was 13.5 per 100,000 
population. There has been a downward trend in HCV notifications since peak numbers (1,538) 
were recorded in 2007, although recent trends indicate that the rate of decline is slowing (Figure 
1.3.1.4). While notifications continued to decline slightly in 2016, trends in notifications of HCV are 
difficult to interpret, as acute and chronic infections are frequently asymptomatic, and most cases 
diagnosed and notified are identified as a result of screening in key risk groups. Therefore, 
notification patterns are highly influenced by testing practices, which may vary over time and may 
not reflect incidence very accurately. 
 
 
 
Figure 1.3.1.4 Number of HCV notifications reported in Ireland, by year of notification, 2007–2016 
Source: HSE and HPSC, 2017  
 
 
Information on the most likely risk factor was available for 47% (n=305) of cases in 2016 (Table 
1.3.1.4). Sixty-seven per cent (n=205) of cases with risk factor data were PWID and 4% (n=13) were 
infected through contaminated blood products. No risk factors were identified for 26 cases for whom 
risk factor data were available despite Public Health follow up. Forty-seven of the cases with no risk 
factor data and 31 cases with risk factor data were from HCV-endemic countries or were known to 
be asylum seekers. 
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Table 1.3.1.4 New HCV cases reported to the HPSC, by risk factor status, 2016 
Risk factor status  n (%) 
Total  645 
    
Cases with reported risk factor data 305 (47.3) 
Of which:   
Injecting drug users 205 (67.2) 
Recipient of blood/blood products 13 (4.3) 
Other risk factors 61 (20.0) 
No known risk factor identified 26 (8.5) 
    
Cases without reported risk factor data 340 (52.7) 
Source: HSE and HPSC, 2017 
 
The proportion of cases attributed to injecting drug use has decreased from 88% in 2011 to 67% in 
2016, but risk factor data were not available for a significant number of cases, so this finding is 
difficult to interpret. Data for 2016 will improve as further validation work is carried out in the coming 
months. 
 
Of the PWID among HCV notifications in 2016, 155 were male and 50 were female, with a median 
age of 39. Seven subjects were under 25 years of age. The majority (71%) resided in Dublin, 
Kildare or Wicklow (Table 1.3.1.5). 
 
 
Table 1.3.1.5 Characteristics of new HCV notifications who reported injecting drug use as a risk factor, 2016 
Known injector cases  n (%) 
Total 205 
    
Gender   
Male 155 (75.6) 
Female 50 (24.4) 
Gender not known 0 
    
Age   
Mean age 39.8 
Median age 39 
Under 25 years 7 (3.4) 
25-34 years 56 (27.3) 
Over 34 years 142 (69.3) 
Age not known 0 (0) 
    
Place of residence   
Dublin, Kildare or Wicklow 145 (70.7) 
Elsewhere in Ireland 60 (29.3) 
Source: HSE and HPSC, 2017 
 
 
1.3.2 Notification of drug-related infectious diseases 
 
Incidence of HCV among PWID in Ireland 
Recent research examined the incidence of HCV infection among PWID in the Republic of Ireland 
over a 13-year period. In this study, which was published in the BMC journal Hepatology, Medicine 
and Policy (Carew, et al. 2017), anonymised data from the National Drug Treatment Reporting 
System (NDTRS) were used to identify all PWID who entered drug treatment for the first time 
between 1991 and 2014. A curve estimating the incidence of injecting was created to plot PWID by 
year of commencing injecting. The curve was adjusted for missing data on PWID in treatment, and 
for injectors who were never treated. An additional adjustment was made to account for PWID who 
had never shared injecting equipment. The incidence of HCV infection and chronic HCV infection 
among PWID was estimated by applying published rates. 
 
It was found that between 1991 and 2014, 14,320 injectors were registered with the NDTRS. The 
majority were young (median age 25 years), male (74%), lived in Dublin (73%) and injected an 
opiate (94%). The estimated total number of injectors up to the end of 2014 was 16,382. The 
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authors estimated that 12,423 (95% CI: 10,799–13,161) individuals were infected with HCV, and 
that 9,317 (95% CI: 8,022–9,966) of these subjects became chronically infected. The estimated 
annual number of new HCV infections among PWID peaked in 1998 (Figure 1.3.2.1). By 2014, 
almost 30% of injectors were estimated to have been infected for over 20 years. 
 
Figure 1.3.2.1 Estimates of new injectors by year commenced injecting and new HCV infections by year infected 
Source: Carew AM, Murphy N, Long J, Hunter K, Lyons S, et al., 2017 
 
 
Research has indicated that the prevalence of opioid use in Ireland may have stabilised  (Hay, et al. 
2017) (see Drugs workbook, Section C, 1.1.2 and 1.1.3), and that the number of PWID entering 
drug treatment for the first time in Ireland has decreased slightly in recent years (European 
Monitoring Centre for Drugs and Drug Addiction 2011). Nevertheless, injecting drug use remains a 
significant issue. As the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
recommends the collection of accurate data on the incidence of injectors entering drug treatment 
(Thanki and Vicente 2013), the study authors concluded that the analysis demonstrates the wider 
usefulness of routine drug treatment data collected by the NDTRS. This may help inform policy with 
regard to the use of highly effective, but expensive, new treatments for HCV that have recently 
become available. 
 
 
1.3.3 Prevalence data of drug-related infectious diseases outside the routine monitoring 
Audit of HCV testing and referral, 2015 
In 2014/15, an unpublished audit was carried out in Ireland of HCV testing and referral in addiction 
treatment centres in HSE Community Healthcare Organisation (CHO) Area 7 (formerly HSE Dublin 
Mid-Leinster). CHO Area 7 covers Dublin 2, 4 (part of), 6, 6W, 8, 10, 12, 16 (part of), 22 and 24. The 
audit was not carried out in the satellite clinics or in West Wicklow and Kildare, as services there are 
in community-based general practice. The number of patients attending the addiction treatment 
centres in CHO Area 7 at the time of starting the audit was 1,255.  
 
The purpose of this audit was to inform the Audit Sub-Group of the Addiction Treatment Clinical 
Governance Committee of CHO Area 7 of compliance with the expected standard of care in relation 
to HCV, and to make recommendations for improvement where necessary. A secondary aim of the 
audit was to collect and collate data on the prevalence of HCV infection in this sample of patients. 
 
Methods  
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A customised audit form was developed. One form was to be completed for each patient attending 
the centre. Data were requested on age, gender, and whether or not the patient was tested for HCV. 
Risk factors for infection, co-infection with HIV, referral to a specialist clinic (hepatology or infectious 
diseases), attendance at a specialist clinic and what level of treatment, if any, was provided were 
also requested. No personally identifiable information was collected on patients. In order to 
encourage cooperation and to avoid making comparisons between centres, the form did not contain 
the name of the doctor or the treatment centre.  
 
A letter, accompanied by the audit form, was sent to 20 GPs in 11 addiction treatment centres in 
CHO Area 7 outlining the audit project and requesting their assistance in completing the forms. A 
total of 319 audit forms were returned, representing 25% of the patients attending the services at 
that time. It is not possible to determine how many doctors or treatment centres participated, as the 
study was anonymous. The main findings from this audit are outlined below. 
 
Findings 
Age and sex 
Where data were available, 63% (198 out of 315 patients) of respondents were male; the age range 
of all respondents was 24 years to 65 years. The median age for males was 38 years, and the 
median age for females was 36 years. The majority of patients (81%) were between the ages of 25 
and 44 years. 
 
Risk factors for HCV infection  
Information on possible risk factors for infection was available for 65% (208 out of 319) of patients 
(Figure 1.3.3.1); of those patients, 85.1% (177 out of 208) had a history of injecting drug use 
(PWID), 10.6% (22 out of 208) had non-injecting drug use risk factors, and 4.3% (nine out of 208) 
had no known risk factors. Of those with non-injecting drug use risk factors, 17 reported cocaine 
use, four reported unprotected sex with a HCV-positive person and one reported both cocaine use 
and unprotected sex with a HCV-positive person. 
 
 
Figure 1.3.3.1 Risk factors for HCV infection among patients* in selected addiction treatment centres in Ireland, 
2014/15 
Source: Unpublished data from the HPSC, 2017 
*Risk factor data available for 65% of patients. 
 
Of the 177 patients who had a history of injecting drug use, 72% (128) were HCV antibody positive 
and 44% (78) were HCV antigen or Polymerase chain reaction (PCR) positive. In those with HCV 
antigen- or PCR-positive results, the age range was 24 years to 56 years, with a median age of 40 
years. The likelihood of having HCV increased with age in those with a history of injecting drug use, 
with 63% (10 out of 16) of 25-34-year-olds testing positive for HCV antigen or PCR compared to 
68% (45 out of 66) of 35-44-yearolds and 80% (20 out of 25) of 45-54-year-olds. Data on HCV 
testing were available for 14 patients, of whom five tested positive for HCV antibodies. Two of these 
five patients were also HCV antigen or PCR positive.  
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HIV infection  
HIV status was recorded on 242 patients, of whom 39 (16%) were HIV positive. The median age of 
HIV-positive patients was 39 years (the full age range was 31 to 56 years). Of the HIV-positive 
patients, 37 were also HCV antibody positive, and 20 of these were HCV antigen or PCR positive. 
The majority (70%) of those co-infected with HIV were male. Where data were available, 97% (34 
out of 35) of all HIV-positive patients were reported to have a history of injecting drug use. Overall, 
19% (34 out of 177) of those with a history of injecting drug use were HIV positive. 
 
Referral to and attendance at hepatology or infectious diseases clinics by gender and age 
Where data were available, 86% (88 out of 102) of HCV antigen or PCR-positive patients were 
referred to a specialist clinic and, of those, 66% (52 out of 79) attended. Males were more likely than 
females to attend a specialist clinic following referral, with a 74% (39 out of 53) attendance rate, 
compared to just 50% (13 out of 26) of females. The likelihood of attendance at a specialist clinic 
also increased with age, with just 36% (four out of 11) of those in the 25-34 age group having 
attended following referral, compared to 68% (30 out of 44) of the 35-44-year-olds and 76% (16 out 
of 21) of the 45-54-year-olds. 
 
Treatment uptake and completion  
Data were collected on whether or not treatment was offered, accepted, completed and successful 
in HCV antigen-positive patients. Out of 105 patients who tested positive for the HCV antigen or 
PCR, data were available on offer of treatment for 57. Of those, 28 patients (49%) were recorded as 
having been offered treatment and 29 were not offered treatment. Of the 28 patients who were 
offered treatment, six were awaiting treatment at the time of the audit, three were still in treatment, 
four had refused treatment and seven had completed treatment; there was no further information on 
the remaining eight patients. Of the seven patients who had completed their treatment, it was 
successful in four, and no information was provided on the remaining three cases. 
 
Conclusions and recommendations 
One aim of this audit was to provide information on the current prevalence of HCV infection in 
patients attending addiction treatment clinics in Ireland. Two-thirds (67%) of patients who had been 
tested were positive for HCV antibodies. This figure is in keeping with previous studies in Ireland 
among PWID, which found the prevalence to be between 62% and 81% (HSE National Hepatitis C 
Strategy Working Group 2012). The prevalence was slightly higher (72%) in those with a recent 
history of injecting drug use. The prevalence of HCV markers was higher in older patients – this may 
reflect their longer injecting history and opportunity for exposure to HCV, or may indicate a reduction 
in incidence in recent years.  
 
Data from nationally collated notifications of HCV infection show a substantial downward trend in 
notifications, and rising age at diagnosis, since peak levels in 2007. However, it must be borne in 
mind that, given the overall low response rate to this audit, the findings may not be representative of 
the population of patients attending addiction treatment services in this region, or in Ireland.  
 
The following were among the recommendations suggested by the audit authors to further the 
understanding of infectious disease prevalence among drug users in Ireland: 
 A computerised patient-management system for addiction treatment clinics is urgently 
needed. This would improve the efficiency of the clinics and make better use of staff 
resources, and would also improve quality of care for patients. 
 The under-resourcing of clinics is an ongoing cause for concern and should continue to be 
highlighted on the HSE Risk Register.  
 Improved communication from specialist hospital clinics to the referring doctors in the 
addiction treatment clinics regarding patients who have been offered treatment would be 
helpful to patient care. In particular, it would be useful for the referring doctor to have timely 
information on the uptake of treatment and response to treatment, and also to know if the 
patient has refused treatment. The HCV liaison nurses may have a role to play in improving 
this information flow.  
 Individual doctors and clinics should be supported in maintaining compliance with HCV 
testing and referral.  
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 Attendance at specialist hepatology and infectious diseases clinics, particularly for younger 
patients, should be encouraged by referring doctors and by the HCV liaison nurses. The 
reasons for poor attendance should be investigated.  
 Addiction treatment doctors and HCV liaison nurses have a role in educating patients about 
the risks and prevention of blood-borne virus transmission, and about the availability of new 
antiviral treatments. 
 
In addition, the authors recommend that the audit should be repeated. It was suggested that the 
next audit should explore the practices in relation to re-testing those patients who initially test HCV 
negative but have ongoing risk-taking behaviour. It should also seek to gather more detailed 
information about treatment uptake and outcomes. A repeat study would be helpful to indicate if 
recently observed increases in the incidence of HIV infection among drug users has been mirrored 
by a rise in HCV infection. It is hoped that the circulation of this report may encourage a better 
response rate for the next audit. A better response would allow for more confidence in the 
representativeness of the findings and would more clearly indicate opportunities for improvement. 
 
1.3.4 Additional information on drug-related infectious diseases 
Pregnant women with blood-borne infections 
 
DOVE clinic, Rotunda Hospital annual report, 2015 
The DOVE clinic in the Rotunda Hospital, Dublin was established to meet the specific needs of 
pregnant women who have, or are at risk of, blood-borne or sexually transmitted bacterial or viral 
infections. Figures from the clinic for 2015 were published in the hospital’s annual report in 2016 
(The Rotunda Hospital 2016). 
 
The number of women admitted to the DOVE clinic for antenatal care for the years 2005–2015 by 
HIV, HBV, HCV or syphilis diagnosis is shown in Figure 1.3.4.1. 
 
Figure 1.3.4.1 DOVE clinic bookings by year, 2005–2015 
Source: The Rotunda Hospital Annual Report, 2016 
 
During 2015, 203 women booked into the DOVE clinic for antenatal care. Of these:  
 
 24 (12%) were positive for HIV infection, a decrease of 4% compared to 2014; 
 64 (32% of bookings) were positive for the HBV surface antigen, representing an increase of 
49% compared to 2014; 
 55 (27%) were positive for the HCV antibody, an increase of 8% compared to 2014; 
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 18 (9%) had positive Treponemal serology, a decrease of 5% compared to 2014; 
 52 (26%) were known to be on prescribed methadone programmes, the same number as in 
2014; and 
 67 women attended treatment for chlamydia trachomatis infection. 
 
Deliveries to mothers attending the DOVE clinic in 2015 are outlined in Table 1.3.6.1. Twenty-five 
were HIV positive, 43 were HBV-positive and 50 were HCV-positive. A total of 69 deliveries were to 
mothers attending the Drug Liaison Midwife (DLM).  
 
Table 1.3.6.1 Deliveries to mothers attending the DOVE clinic who were positive for HIV, HBV, HCV or syphilis or 
who were attending the DLM, 2015 
Mothers status HIV(+ve) HBV(+ve) HCV(+ve) Syphilis 
(+ve) 
DLM 
Total mothers delivered 25 43 50 16 69 
Total mothers delivered <500g 
(incl miscarriage) 
1 3 2 1 7 
Total mothers delivered >500g 24 40 48 15 62 
Live infants 25* 40*
#
 50**
 
15 63* 
Miscarriage 1 3 3*
 
1 7 
Stillbirth 0 2
#
 0
 
0 0 
Infants <37 weeks gestation 
 
2 3 7 4 11 
Infants >37 weeks gestation 
 
23 37 43 11 52 
Caesarean section 11 
 
14 20 2 24 
HIV, HBV, HCV or syphilis 
positive infants 
0 
 
0 0 0 - 
Maternal median age 34 30 31 34 - 
Newly diagnosed NAS  2 8 8 4 
 
15
## 
Source: The Rotunda Hospital Annual Report, 2016 
* Including one set of twins. 
** Including two sets of twins. 
# 
Including one baby of a set of twins. 
##
 Neonatal intensive care unit admission for NAS. 
NAS = Neonatal abstinence syndrome 
DLM = Drug Liaison Midwife. 
 
Coombe Women and Infants University Hospital annual report, 2014 
In 2015, the Coombe Women and Infants University Hospital published its annual report for 2014 
and reported that 278 women had attended the Addiction and Communicable/Infectious Diseases 
Service for antenatal care and postnatal follow-up (Coombe Women and Infants University Hospital 
2016).  
 
Of those attending antenatal care: 
  
 36 were positive for HBV, of whom 10 were newly diagnosed; 
 52 were positive for HCV, of whom eight were newly diagnosed; 
 24 were positive for HIV, of whom none were newly diagnosed; and 
 four were co-infected with HCV, but none were co-infected with either HBV or syphilis. 
 
In terms of addiction, 64 women were linked with the DLM. Of these 64 women, 41 delivered 41 live 
babies. Of the 41 babies, 20 were admitted to special care. Of these 20 babies, 15 required 
pharmacological treatment for NAS. The report states that heroin continues to be the primary 
substance used, but cocaine and benzodiazepine use was also evident. 
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1.4 Other drug-related health harms 
 
1.4.1 Other drug-related health harms 
 
National Registry of Deliberate Self-Harm annual report, 2015 
The 14th annual report from the National Registry of Deliberate Self-Harm was published in 2016 
(Griffin, et al. 2016). The report contains information relating to every recorded presentation of 
deliberate self-harm to acute hospital emergency departments in Ireland in 2015, and complete 
national coverage of cases treated. All individuals who were alive on admission to hospital following 
deliberate self-harm were included, along with the methods of deliberate self-harm that were used. 
Accidental overdoses of medication, street drugs or alcohol were not included.  
 
Rates of self-harm 
There were 11,189 recorded presentations of deliberate self-harm in 2015, involving 8,791 
individuals. This implies that more than one in five (21%) presentations was a repeat episode. 
Taking the population into account, the age-standardised rate of individuals presenting to hospital in 
the Republic of Ireland following self-harm was 204 per 100,000 population. This is similar to the 
rate recorded in 2014 (200 per 100,000). There were successive decreases in the self-harm rate 
between 2011 and 2013; nevertheless, the rate in 2015 was still 9% higher than in 2007, the year 
before the economic recession (Figure 1.4.1.1). 
 
Figure 1.4.1.1 Person-based rate of deliberate self-harm from 2002 to 2015 by gender  
Source: National Suicide Research Foundation, 2016 
‘All’ in the legend refers to the rate for both men and women per 100,000 population 
 
 
In 2015, the national rate of self-harm among males was 186 per 100,000, 1% higher than in 2014. 
The rate among females was 222 per 100,000, which was 3% higher than in 2014. Since 2007, 
male and female rates of self-harm have increased by 15% and 3%, respectively. With regard to 
age, when compared to 2014, the only significant change in the rate of hospital-treated self-harm 
was among men aged 35-39 years, where the rate increased by 15% from 220 per 100,000 to 253 
per 100,000. The authors noted that increasing rates observed in males is particularly worrying 
considering the higher lethality of self-harm methods among men. 
 
 
Self-harm and drug and alcohol use 
Intentional drug overdose was the most common form of deliberate self-harm reported in 2015, 
occurring in 7,319 episodes (65%). As observed in 2014, overdose rates were higher among 
women (71%) than among men (59%). Minor tranquilisers, paracetamol-containing medicines and 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Men 167 177 170 167 160 162 180 197 211 205 195 182 185 186
Women 237 241 233 229 210 215 223 222 236 226 228 217 216 222
All 202 209 201 198 184 188 200 209 223 215 211 199 200 204
100
120
140
160
180
200
220
240
260
R
a
te
 p
e
r 
1
0
0
,0
0
0
 p
o
p
u
la
ti
o
n
 
23 
 
antidepressants/mood stabilisers were involved in 38%, 29% and 20% of drug overdose acts, 
respectively. In 69% of cases, the total number of tablets taken was known, with an average of 28 
tablets taken in episodes of self-harm that involved a drug overdose. 
 
There was an 18% increase in the number of presentations involving street drugs (cannabis, 
ecstasy and cocaine), which rose from 465 in 2014 to 547 in 2015, following annual decreases from 
2010 to 2013. The 2015 level is the highest recorded since 2008 and the second highest ever 
recorded by the registry. Alcohol was involved in 31% of all self-harm presentations, and was 
involved significantly more often in male episodes of self-harm than in female episodes.  
The authors concluded that these findings underlined the need for on-going efforts to: 
 reduce access to minor tranquilisers and other frequently used drugs; 
 further research to examine the sources of illicit drugs used in intentional overdoses; 
 intensify national strategies to increase awareness of the risks involved in the use and 
misuse of alcohol; and 
 further strategies to reduce access to alcohol.  
 
The report highlighted the ongoing work by the National Suicide Research Foundation to link data 
on deliberate self-harm with suicide mortality data. This linking has shown that individuals who self-
harm are over 42 times more likely to die by suicide than the general population. Further linkage is 
recommended in order to enhance insight into predictors of suicide risk.  
 
Self-harm, alcohol consumption and public holidays 
Research that has recently been published in the Journal of Affective Disorders (Griffin, et al. 2017), 
highlights the effect of alcohol consumption on self-harm presentations to Irish hospital emergency 
departments during public holidays.  
 
The National Self-Harm Registry Ireland has consistently shown peaks in self-harm presentations 
out of hours at weekends and during public holidays. Presentations involving self-harm peak around 
midnight, and approximately one-third of presentations are recorded on Sundays and Mondays. In 
recent years, peak attendances have been observed on public holidays. During the period from 
2007 to 2015, the mean number of self-harm presentations was 27 daily and 32 on public holidays. 
Across all years, St Patrick’s Day and New Year’s Day showed higher numbers of presentations 
compared to other public holidays, with a yearly average of 44 and 41, respectively. 
 
It was found that alcohol was involved in 43% of self-harm presentations on public holidays 
compared to 38% on all other days. Self-harm presentations had a 24% increased likelihood of 
involving alcohol on public holidays compared to all other days (relative risk: 1.24, 95% CI: 1.17–
1.32). In addition, self-harm presentations to hospital on Christmas Eve, Christmas Day and New 
Year’s Eve had an 80%, 77% and 62% increased probability of involving alcohol, respectively 
(Figure 1.4.1.2).  
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Figure 1.4.1.2 Association between alcohol consumption and self-harm presentations during public holidays  
Source: Griffin E, Dillon CB, O’Regan G, Corcoran P, Perry IJ, et al., 2017 
 
The authors concluded that the findings support the hypothesis that self-harm presentations are 
elevated on public holidays and that alcohol consumption is more strongly associated with self-harm 
presentations on public holidays. 
 
These findings highlight the need for continuing efforts to:  
 
 enhance health service capacity at specific times;  
 increase awareness of the negative effects of alcohol misuse and abuse; 
 educate self-harm patients and their families about the importance of reduced use of, and 
access to, alcohol; 
 arrange active consultation and collaboration between the mental health services and 
addiction treatment services in the best interest of patients who present with dual diagnosis 
(psychiatric disorder and alcohol/drug abuse); and  
 ensure the assessment of alcohol and other substance misuse and abuse is a structural part 
of the assessment to determine the risk of repeated self-harm and suicide. 
 
 
1.5 Harm reduction interventions 
1.5.1 Drug policy and main harm reduction objectives 
The strategic aims and objectives of the current drugs strategy (Department of Community 2009) 
with regard to harm reduction interventions include the following:  
 
 To enable people with drug misuse problems to access treatment and other supports and to 
reintegrate into society. 
 To reduce the risk behaviour associated with drug misuse. 
 To reduce the harm caused by drug misuse to individuals, families and communities. 
 To encourage and enable those dependent on drugs to avail of treatment with the aim of 
reducing dependency and improving overall health and social wellbeing, with the ultimate 
aim of leading a drug-free lifestyle.  
 To minimise the harm to those who continue to engage in drug taking activities that put them 
at risk. 
 
For further details on the drugs strategy, see Section 1.1 of the Policy workbook. 
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1.5.2 Organisation of harm reduction services 
Regional Drug and Alcohol Task Force (RDTF) areas in Ireland offer harm reduction programmes 
including needle exchange from fixed sites, mobile units and outreach work. Outreach workers 
frequently practise ‘backpacking’ – a process whereby staff, in the absence of a local clinic or 
mobile unit – carry supplies of drug-taking paraphernalia for distribution to known drug misusers 
(Moore, et al. 2004). 
 
Additional support services operate from sites in the greater Dublin in addition to a number of 
Dublin-based or national community-based organisations (CBOs) such as Merchants Quay Ireland 
(MQI) and the Ana Liffey Drug Project (ALDP). Some of these services are seasonal or simply on a 
fixed-time, once-per-week basis. Harm reduction services report initiatives including free needle 
exchange; providing alcohol wipes, sterile water, citric acid filters, spoons and condoms; the 
provision of methadone and naloxone therapy; and rehabilitation, education and community/family 
support. In addition, there are pharmacies providing needle exchange in each RDTF area in Ireland 
apart from those covering counties Dublin, Kildare and Wicklow.   
 
1.5.3 Harm reduction services 
 
Harm reduction services: Community-Based Organisations (CBOs) 
 
Merchants Quay Ireland (MQI) annual review, 2015 
MQI is a national voluntary agency providing services for homeless people and for drug users. In 
2015, there were 19 MQI locations in 11 counties in the Republic of Ireland (Figure 1.5.3.1). In 
September 2016, MQI published its annual review for 2015 (Merchants Quay Ireland 2016). 
 
 
Figure 1.5.3.1 MQI locations in Ireland 
Source: MQI, 2016 
1. Dublin; 2. Shelton Abbey, Co. Wicklow; 3. St Francis Farm, Co. Carlow; 4. Cork city; 5. Limerick city; 6. Co. Offaly; 7. 
Co. Westmeath; 8. Portlaoise town, Co. Laois; 9. Co. Longford; 10. Castlerea town, Co. Roscommon; 11. Loughran 
House, Co. Cavan.  
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MQI: Open access drug services 
Assertive Outreach Service (AOS) 
In line with the MQI mission statement to reach out to the most vulnerable in society, this service 
aims to make contact with drug users not engaged with other services and to provide them with 
accessible support options. In 2015, the AOS contacted vulnerable drug users on the street, 
collected used needles and syringes and liaised with local community groups, including police, 
Dublin City Council and other drug and homeless service providers. The geographical zone covered 
by the AOS is predominantly around each MQI location (Figure 1.5.3.1).  
 
AOS workers also liaised with a variety of other businesses, residents, individual tourists, and 
services. Clients were assisted with accommodation, drug treatment options, clothing, food, 
showers and basic services. The AOS visited a number of clients in hospitals and nursing homes 
throughout the year. This involved working with medical staff and social workers to progress care 
plans. MQI workers also accompanied service users to doctors, court, post offices and case 
conference meetings. The service engaged with 55 homeless individuals in specific casework, and 
with over 1,000 individuals on an informal support basis, throughout 2015. 
 
Intensive Engagement Service (IES) 
Many of the drug users who avail of MQI’s Open Access Homeless and Drug Services are 
homeless and have financial and legal problems. The MQI morning service (10.00 to 1pm) has 
transitioned from a drop-in service to a one-to-one support function called the Intensive 
Engagement Service (IES). This service operated throughout 2015, resulting in a smaller number of 
visits but an increased depth of work on individual needs, providing support with accommodation, 
treatment and training, as well as with medical, welfare and legal issues. This service also provides 
continuity of care, as it may sometimes take weeks or months of working with multiple support 
agencies in order to attain outcomes for clients. In maintaining contact with clients, MQI is able to 
assist both clients and partner agencies by filling out paperwork or getting signatures on medical 
card applications, homeless registrations or treatment referral forms. In 2015, 1,008 individuals 
availed of the IES, visiting the service 2,761 times. Each of the 1,008 individuals accessing the IES 
was provided with options to see specialist in-house supports, such as the Young Persons Support 
Worker, medical staff or drug treatment specialists. 
 
 
MQI: Harm reduction services 
These services may be accessed by drug users simply by walking in from the street. For this 
reason, MQI is often the first place people with drug problems turn to for help in the Republic of 
Ireland. 
 
Health Promotion Unit 
This unit provides drug users with information about the risks associated with drug use and the 
means to minimise such risks. MQI offers drug users a pathway into treatment and the possibility of 
living a life without drugs. In the needle exchange and health promotion service, the main focus is 
on reducing the harms associated with injecting drug use, fostering the motivation to make positive 
change, giving advice on HIV, HBV and HCV prevention, and providing information on overdose 
and other risks. MQI also offers early referral to drug treatment services. 
 
In 2015, there were 27,388 visits to drug services, an increase of 4% on the number of visits in 
2014. As part of the MQI health promotion remit, a total of 1,643 safer injecting workshops were 
undertaken with PWID in 2015. Many of these interventions were with new injecting drug users, and 
are an important part of early intervention where people are given treatment options and advice on 
the dangers of injecting drugs. 
 
The Naloxone Demonstration Model (NDM) 
Along with partners in the HSE, the Family Support Network and the ALDP, MQI was front and 
centre in the national roll-out of the Naloxone Demonstration Model (NDM) in 2015. To date, more 
than 100 drug users have been prescribed naloxone, and an external evaluation concluded that the 
scheme was a success. Since the NDM began, there have been five recorded ‘overdose reversals’ 
which may have contributed to lives being saved. In 2015, 600 individuals were trained in how to 
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use naloxone. Future developments include providing accredited training in order to supply the 
mechanisms to support the statutory changes required to make this product more widely available in 
Ireland.  
 
 
MQI: Support services 
Methadone prescribing – Treatment and support 
In 2015, MQI collaborated with the GPs from Safetynet, an accessible health service for people 
experiencing homelessness, in providing methadone substitution therapy to 20 service users. 
 
Into Education and Employment: Stabilisation Programme (IEE) 
As part of MQI support services, Into Education and Employment (IEE) offers therapeutic groups, 
life skills training, personal development work and pre-employment training to help drug users 
reintegrate into society. Links with the City of Dublin Education and Training Board allow MQI to 
include a strong educational component within this programme, with clients gaining Quality and 
Qualifications Ireland (QQI) accreditation on some courses. This is of considerable importance in 
addressing the educational disadvantage experienced by many drug users. The MQI’s IEE 
programme had 66 participants during 2015, an increase of 43% from the number of participants in 
2014, with course content consisting of art therapy, cooking, drama, yoga, gardening, therapeutic 
group work, history, maths, and educational and social outings. Clients using this service were 
predominantly younger people, with 79% of participants aged between 25 and 39 years.  
 
The IEE group seeks to establish a regular pattern of discipline and attendance in order to prepare 
people for mainstream training and employment. Although not all clients stayed with the programme 
in 2015, and some relapsed into chaotic drug use, MQI noted that many people did progress to 
training, work experience and a more structured, abstinence-based treatment. This programme 
operates with a low threshold ethos, seeking to keep clients engaged. 
 
Family Support Group (FSG) 
MQI offers one-to-one advice and support to family members on the realities of drug use and how 
they can best cope and provide optimum support to drug users. MQI also runs a Family Support 
Group (FSG), which meets every week and provides a forum where parents, as well as other close 
relatives and friends of drug users, are offered support and advice on a range of issues. Participants 
provide support for each other, and the group is continually open to new members. The weekly FSG 
is linked to the National Family Support Network, which offers an opportunity to raise issues at a 
national level. MQI’s FSG in Dublin worked with 30 individuals throughout 2015. 
 
 
MQI: Midlands Services 
With support and funding from the Midlands Regional Drug and Alcohol Task Force (MRDTF) and 
the HSE, MQI provides services in the four Midlands counties of Laois, Longford, Offaly and 
Westmeath. The MQI Family Support and Community Harm Reduction Team was established in 
late 2008 and provides dedicated outreach services for individuals actively using drugs. It also 
provides Family Support Services focused on the needs of the families of active drug users. The 
Midlands team consists of MQI staff, Department of Social Protection participants, those on work 
placement and volunteers working across these four Midlands counties. 
 
Rehabilitation and Aftercare Service 
MQI, with the support of the MRDTF and the HSE, established the Rehabilitation and Aftercare 
Service in September 2010. The purpose of this service is to provide a range of rehabilitation and 
aftercare supports targeting clients from the region, including those exiting drug treatment and 
prison. This involves assisting clients in the process of regaining their capacity for a daily life free 
from the impact of problem drug use and enabling their reintegration into the community. MQI 
workers provide case management for clients with a view to ensuring that all clients have their 
needs assessed and that they have the opportunity to participate in developing a care plan offering 
a pathway towards rehabilitation.  
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Workers also provide psychosocial support for persons leaving drug treatment or prison via one-to-
one support and aftercare group work. This service worked with 75 individuals in 2015. The team 
liaised closely with interagency partners in order to address the underlying issues of addiction: 
accommodation, healthcare and abuse. Service users were both supported and challenged in terms 
of meeting their care plan goals and received one-to-one interventions and group support where 
required. There were 359 one-to-one sessions and 103 groups facilitated in 2015.  
 
 
Athlone Open Door Centre (ODC) 
The Athlone Open Door Centre (ODC) provides a range of services for drug users in Athlone. These 
include a drop-in centre offering crisis support, food service, washing and laundry facilities, 
vocational training initiatives and support towards rehabilitation and reintegration. The service is 
focused on providing crisis support and offering progression pathways for clients. It operates in 
partnership with the Department of Social Protection, HSE, Educational and Training Board, GPs 
and other interagency partners in the Midlands region. As part of the harm reduction and 
rehabilitation process, the Athlone ODC team worked closely with a group of 114 individuals in 
2015, many of whom attended on a regular basis. 
 
Clients make use of facilities within the centre as well as one-to-one counselling sessions with 
project workers. The ODC team develops therapeutic relationships with clients through a focused, 
non-judgemental approach to their work. In 2015, there were 114 individuals (91 male and 23 
female) using the service, and there were 3,395 visits to the centre, which included the provision of 
3,014 meals, 204 showers, 211 laundry services, and 2,850 advice and support sessions. 
 
Midlands Family Support Services  
These services involve the provision of interventions that support families in coping with addiction-
related issues. Such services often include counselling, guidance and advice. Under the drugs 
strategy, family support is seen as increasingly important in the areas of drug treatment and 
prevention.  
 
The MQI Midlands Family Support Services assist families to: 
 
 deal with the trauma associated with a family member or loved one using drugs; 
 work with vulnerable families in the area of drugs prevention; 
 act as a reliable source of information on drug use and related issues; 
 deal with the reaction of neighbours and others; 
 overcome self-blaming responses; 
 create positive coping strategies that will help the family and drug user make positive 
decisions; 
 build their capacity to respond; 
 set rules of behaviour for those living in their house; and 
 challenge views that the family caused the drug use problem, can control it, or can cure it. 
 
These services also provide one-to-one sessions by appointment for parents and other close 
relatives of drug users seeking advice and support. MQI works to proactively link people with other 
support or treatment services that may be relevant to their needs. In 2015, the project engaged with 
87 individuals, provided 1,011 support phone calls and facilitated 203 family support groups, 
including one-to-one support sessions where required. 
 
 
Midlands Community Harm Reduction Services 
MQI is aware that local people and organisations are often very concerned about the level of public 
and community harm associated with drug use in their communities, as well as the risks that drug 
users may expose themselves to. Therefore, the aims of these services are to: 
 
 act as a resource for community groups in their efforts to minimise the impact of problem 
drug use on their communities; 
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 reduce the level of individual and community harm experienced in local communities as a 
result of drug use; 
 reduce the associated level of public health risk experienced in designated areas; 
 provide harm reduction and crisis support services to local drug users in places, and at 
times, where such services are unavailable;  
 ensure that problems associated with drug use are minimised; and  
 promote a partnership model between Residents Associations, Estate Management 
Committees, Community Policing Services and Midlands services in tackling drug issues at 
a local level. 
 
 
Midland Day Programme 
MQI launched a Department of Social Protection Community Employment Scheme based in the 
Athlone ODC at the end of 2014. This day programme continued to operate successfully in 2015 
and provided 15 individuals with employment and training tailored to their specific goals in life. 
Securing employment is a significant step for those seeking to permanently exit lifestyles involving 
drugs and homelessness. Rehabilitation and aftercare were incorporated into the scope of harm 
reduction outreach workers in the Midlands area. This is in line with international research indicating 
what works in drug treatment, thus ensuring that people who have achieved abstinence are given 
the vital support they need to maintain drug-free lifestyles as a part of their individual care plan. 
 
 
Midlands Resettlement Service 
Post-treatment settlement is an ongoing issue, and in 2015 the Midlands Resettlement Service 
continued working relationships with county councils, accommodation providers and property 
owners in order to secure or maintain housing for those at the margins of homelessness. The 
Midlands team works on individual cases in order to ensure that recovery pathways out of 
homelessness and addiction are consolidated through maintaining accommodation with support. 
Further treatment and progression options are a central part of the work of MQI in order to progress 
pathways for drug users back into mainstream society. 
 
 
MQI: Drug-free treatment services 
St. Francis Farm (SFF) Residential Rehabilitation and Detox Services 
The Rehabilitation Service at St. Francis Farm (SFF) offers a 13-bed therapeutic facility with a 14-
week rehabilitation programme set on a working farm in Co. Carlow. At SFF, MQI provides a safe 
environment where service users can explore the reasons for their drug use, adjust to life without 
drugs, learn effective coping mechanisms and make positive choices about their future. 
 
There were 377 clients referred to the SFF Residential Rehabilitation Service during 2015, a 6% 
increase compared to the number of referrals in 2014. In addition, there were 272 assessment 
appointments offered to clients referred. Of these, 178 attended their assessment appointment. In 
2015, a total of 51 individuals were admitted to the programme – 37 men and 14 women. This 
represents an 11% increase in admissions compared to 2014. In addition to clients’ addiction needs, 
49% of clients were homeless and 50% were the subject of criminal justice orders on admission. 
 
The Residential Detoxification Service at SFF delivers both methadone and combined 
methadone/benzodiazepine detoxes. This unit has a 10-bed capacity for men and women, and the 
detox activity programme includes individual care planning, therapeutic group work, psycho-
educational workshops, fitness/gym training and farm work activities. 
 
A total of 347 assessment appointments were offered to referred clients during 2015 – 250 males 
and 97 females. This was a 29% increase compared to the 269 assessment appointments offered in 
2014. There were 63 clients admitted for detox services during 2015 – 47 men and 16 women. All of 
the 63 clients admitted to SFF detox services in 2015 were on prescription methadone. The length 
of time individual clients were on methadone prior to admission ranged from one to 28 years. Of the 
63 clients who departed the service during 2015, 83% completed their detox, a 14% increase 
compared to 2014.   
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SFF has a national catchment area, and in 2015 accepted admissions from 20 counties, with Dublin 
and Cork being the largest sources of clients. 
 
 
Ana Liffey Drug Project (ALDP) 
The ALDP is a ‘low-threshold harm reduction’ project working with people who are actively using 
drugs and experiencing associated problems. The ALDP has been offering harm reduction services 
to people in the North Inner City area of Dublin since 1982, from two premises at 48 and 51 Middle 
Abbey Street. Across these two buildings they offer a wide variety of low threshold, harm reduction 
services that offer drug users pathways out of their current circumstance, including addiction and 
homelessness. 
 
The ALDP is committed to impacting positively on the neighbourhood and the wider community. 
Subsequently, they are active in managing antisocial behaviour in the area and, in return, receive 
ongoing support from the local business community. 
 
The services offered in Dublin are: 
 Open Access 
 Assertive Outreach 
 Needle and Syringe Programme 
 Medical Services 
 Stabilisation Group 
 Detox Group 
 Harm Reduction Group  
 Treatment Options Group 
 Assessment for Residential Treatment 
 Key Working and Case Management 
 Prison Inreach 
 
The ALDP Mid-West region provides harm reduction services in Limerick city and three counties to 
people affected by problem substance use, their families and the wider community. The counties 
served are: 
 
 Limerick 
 Clare 
 North Tipperary 
 
The services offered in the Mid-West region are: 
 
 Open Access 
 Assertive Outreach 
 Needle and Syringe Programme 
 Medical Services 
 Harm Reduction Group 
 Assessment Group for Residential Treatment 
 Pre-entry to the Helping Women Recover Group 
 Key Working and Case Management 
 Prison Inreach 
 
The ALDP Online and Digital Services team also offers support and information to the general 
public, to drug users, and to other agencies that work with problem drug users. 
 
 
Harm reduction services: Needle exchange 
There are three models of needle exchange programmes in use in Ireland: 
 
 Static – 24 sites, mainly in Dublin city 
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 Outreach – 14 sites mainly in counties Dublin, Kildare, Laois, Offaly, Waterford and Wicklow 
 Pharmacy – 111 sites in regions outside Dublin, Kildare and Wicklow 
 
Data on the number of syringes exchanged from static and outreach sites were unavailable for this 
report. Information on pharmacy-based needle exchange in Ireland is discussed in the following 
sections. 
 
 
Pharmacy-based needle exchange: Overview, assessment and needles exchanged 
 
Pharmacy-based needle exchange: Overview 
The current drugs strategy aims to reduce harms arising from substance misuse and to reduce the 
prevalence of blood-borne viruses among PWID through the expansion of needle exchange 
provision to include community pharmacy-based programmes (Department of Community 2009). 
 
In October 2011, the HSE rolled out the national Pharmacy Needle Exchange Programme, which is 
a partnership initiative between the Elton John AIDS Foundation, the Irish Pharmacy Union and the 
HSE. Once pharmacies have signed a service level agreement with the HSE, their contact details 
are passed on to the relevant HSE services so that they can promote access to sterile injecting 
equipment at the participating pharmacies and accept referrals for investigation and treatment. 
There are pharmacies providing needle exchange in each RDTF area, apart from those covering 
counties Dublin, Kildare and Wicklow, which are served by a mix of static and outreach needle 
exchange programmes. At the end of 2016, there were 111 pharmacies providing needle exchange 
(Table 1.5.3.1). 
 
Table 1.5.3.1 Number of pharmacies providing needle exchange in Ireland by RDTF area, 2011–2016 
RDTF area 2011 2012 2013 2014 2015 2016 
Midland (Longford, Laois, Offaly, 
Westmeath) 
5 13 15 16 17 18 
North Eastern (Meath, Louth, Cavan, 
Monaghan) 
3 9 16 21 22 21 
North West (Sligo, Leitrim, West 
Cavan, Donegal) 
3 4 7 6 6 6 
Southern (Cork and Kerry) 8 10 16 21 19 21 
South East (Carlow, Kilkenny, 
Waterford, Wexford, South Tipperary) 
13 21 22 24 17 17 
Western (Galway, Mayo, Roscommon) 5 2 10 13 11 12 
Mid-West (Clare, Limerick, North 
Tipperary) 
5 8 13 14 15 16 
Total 42 67 99 115 107 111 
Source: Unpublished data from HSE, 2017 
 
 
Pharmacy-based needle exchange: Assessment 
In line with best practice, the Steering Group of the HSE Pharmacy Needle Exchange Programme 
commissioned Liverpool John Moores University – in partnership with Waterford Institute of 
Technology – to carry out an external evaluation (Bates, et al. 2015). This study was undertaken to 
evaluate the three-year pilot stage of the programme and the progress in delivering needle 
exchange services to PWID. It aimed specifically to:  
 
 understand client and stakeholder satisfaction with needle exchange and attitudes towards, 
and experiences of, these services; 
 provide information relating to safer injecting, safer sexual behaviour, and the prevalence of 
blood-borne viruses that can be compared to international literature and to data collected 
during future evaluations; and 
 provide recommendations regarding the development and delivery of services and policy. 
 
This section presents the methodology and main findings from this study. 
 
Methodology 
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All pharmacies participating in the programme in April 2014 were eligible to take part in the study, 
and staff were asked to complete an online survey. Pharmacy staff were also requested to opt in to 
additional parts of the research, including participating in an interview with a member of the 
research team.  
 
Pharmacies were provided with questionnaires that staff were requested to ask any client using the 
needle exchange to complete. Visits were made to five of the 10 pharmacies participating in the 
programme that had the greatest number of monthly transactions, where needle exchange clients 
were approached and asked if they would like to participate in the study through an interview. A 
brief online consultation with stakeholders was also undertaken, examining their perceptions of the 
programme effectiveness and identifying strengths, weaknesses, and areas for further development. 
 
Main findings 
 
Pharmacy staff results 
Experience of service provision  
Pharmacy staff reported a variety of successes. The service was described in interviews as quick 
and efficient, with minimal impact on the running of other pharmacy activities. However, uptake was 
viewed as sporadic in some sites, with comments around levels of heroin availability impacting on 
injecting rates. Increasing uptake was reported in some sites, but with no change in gender profiles. 
Although a majority of staff reported positively about the needle exchange and clients, negative 
impacts of the service identified by small numbers of staff included the risk of crime and undesirable 
behaviour in the pharmacy and surrounding area. In addition, where pharmacies were located within 
shopping areas, it was apparent that some local businesses and security objected to the needle 
exchange. 
 
Engagement and trust in needle exchange  
The majority of staff surveyed believed they had engaged well with clients, although difficulties 
identified included a lack of interest in engagement from some clients. The exchange itself was 
described by the majority of interviewed staff as a quick process, with service users appearing 
anxious to leave the site. Lack of interaction was generally due to service users’ reluctance to 
engage and pharmacists’ lack of time. While it was noted that clients may like the speedy 
transaction, it was also recognised that this limits the opportunity to offer further intervention. First 
contact characterised by friendliness on the part of the pharmacist and frontline staff was viewed by 
many as being vital when initially developing positive and trusting relationships with service users. 
 
Needle and equipment provision  
Pack size options were described by the majority of interviewees as optimising efficiency and 
discretion for the user. However, some staff observed that service users reported that the needles 
and syringes provided were not the right size or the right volume, and identified that needles for 
groin injecting would be a useful addition. Further potential additions to packs that were suggested 
by pharmacy staff included tourniquets and condoms. The needle exchange transaction itself was 
viewed as efficient, but in some instances was hampered by poor dialogue between pharmacists 
and service users, as well as low return rates.  
 
 
Training and information needs 
The most frequent response when staff were asked to identify methods to improve the service was 
the provision of more information through training about local services and helplines, as well as 
refresher courses in response to emergent drug issues and service needs. In particular, training 
regarding performance- and image-enhancing drugs, such as steroids and melanotans, was 
commonly requested. The majority of pharmacies engaged with local community drug services and 
methadone clinics, but observed the need for greater visibility of services and referral routes. 
 
Client-reported outcomes  
Client satisfaction with services  
The survey sample (n=74) included 23 females and 46 males with a mean age of 32 years (five 
clients did not report their gender). The majority (88%) reported using heroin, with less than 15% 
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reporting use of any other drug. Generally, PWID reported high satisfaction with service provision, 
including the injecting kits provided, pharmacy location, opening hours, staff knowledge and 
information provision. A minority of clients reported dissatisfaction with the attitudes of staff (24%) 
and privacy within the needle exchange (30%), with lower satisfaction on both criteria among 
females. Experiences of accessing the pharmacies were generally positive, with few comments 
around stigma associated with injecting drug use or uncomfortable feelings on accessing the 
pharmacy. Additionally, participants were satisfied with the confidential nature of the exchange. 
Pharmacy staff were viewed as friendly and polite, with the primary reasons stated for using specific 
pharmacies being related to location of the pharmacy and staff attitude. 
 
Client behavioural outcomes  
Self-reported rates of HBV, HCV and HIV diagnosis were 7%, 22% and 5%, respectively. 
Approximately one-third of clients reported never having been tested for each of these blood-borne 
viruses. Almost half (49%) of the survey sample reporting having used a needle with which 
someone else had already injected, with 28% having done so in the past month. Females were 
more likely than males to have shared a needle ever, or in the past month. Approximately half (47%) 
of clients reported having multiple sexual partners in the past month, including a small proportion 
with five or more partners (7%). A minority (39%) of clients reported always using a condom during 
sexual intercourse.  
 
Stakeholder survey  
Six stakeholders completed the survey, including representatives from drug services, the Irish 
Pharmacy Union, and outreach services. Overall, the programme was rated as being ‘very effective’ 
(n=3) or ‘somewhat effective’ (n=3). Key strengths identified included the increase in availability and 
accessibility of needle exchange services, and the impact of this on access to equipment and health 
professionals. Perceived weaknesses included difficulties encouraging returns, the need for a ‘pick 
and mix’ service as opposed to premade, pre-prepared packs (which are not suitable for all clients), 
a lack of signposting to other services, and the identification of some stigma affecting needle 
exchange relations with local businesses and customers.  
 
Conclusions and recommendations 
Overall, the evidence from the study suggests that the Pharmacy Needle Exchange Programme is 
acceptable and accessible to PWID in Ireland, and that it is largely supported by pharmacy staff. 
Nevertheless, despite these successes, a number of recommendations were suggested that might 
help improve service provision and further meet client needs. These included the following: 
 
 Provide a wider range of equipment or packs suitable for all clients. Additionally, the 
possibility of providing ‘pick and mix’ services, in addition to pre-prepared packs, may better 
meet client needs. 
 Develop integrated care pathways to link the exchange programme with other services for 
PWID, such as drug agencies and sexual health services. As more health interventions 
become embedded within the pharmacy, this is likely to become increasingly important to 
prevent pharmacies from becoming isolated from other related organisations providing 
services for injecting drug users. 
 Consider offering in-pharmacy testing for blood-borne viruses. Where this is not possible, 
ensure that pharmacy staff are provided with sufficient information on local services to 
enable efficient referral processes and signposting.  
 Increase the frequency of training provision for pharmacy staff and include information about 
anabolic steroids, melanotans, and associated performance- and image-enhancing drugs to 
help staff provide services to clients who inject these drugs. Training should be constantly 
reviewed to ensure that it is meeting the needs of pharmacy staff. The profile of PWID is 
likely to change, and therefore the knowledge and skill requirements of staff will change too, 
leading to the need for top-up training.  
 Ensure that staff have sufficient training and knowledge about drug use and health-related 
issues to confidently provide harm reduction advice and support.  
 Encourage (through training and information for staff) a consistent approach to increase 
returns and improve engagement with clients. Additionally, build on current work being 
undertaken regarding appropriate community responses to drug-related litter.  
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 Oversee the transition from a paper-based monitoring system to an electronic data 
monitoring system to be used by all participating pharmacies.  
 
As well as these recommendations, the authors suggest that future evaluations should use the 
same survey procedures to allow comparison of outcomes as an indication of programme 
development. In addition, the possibility of collecting biological samples from clients was also 
mentioned.  
 
 
Pharmacy-based needle exchange: Number of needles exchanged 
Figure 1.5.3.2 shows the number of individual needles exchanged from pharmacy-based sites for 
the years 2015 and 2016, by month. There were a total of 277,305 individual syringes exchanged in 
2015 and 279,154 exchanged in 2016. 
 
 
Figure 1.5.3.2 Number of individual needles exchanged from pharmacy-based sites by month, 2015 and 2016 
Source: Unpublished data from HSE, 2017  
 
Figures 1.5.3.3 and 1.5.3.4 show the number of persons who attended pharmacy-based needle 
exchanges in 2015 and 2016. It should be noted that the sex breakdown is based on unique male 
and female individuals attending each month, and not on how many persons attended, or how many 
needles were exchanged by each person. An average of 1,604 persons attended pharmacy-based 
needle exchanges each month in 2015 (compared to an average of 1,330 per month in 2014), and 
an average of 1,614 persons attended each month in 2016. In both years and each month, the 
majority of individual attendees were male.  
 
 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2015 20812 19095 21045 22361 23127 23939 25558 24608 24057 23740 23316 25647
2016 21245 21437 21533 23449 23774 22756 23794 25713 25288 23179 22843 24143
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Figure 1.5.3.3 Number of persons attending needle exchange, by month and gender, 2015 
Source: Unpublished data from HSE, 2017 
 
 
 
Figure 1.5.3.4 Number of persons attending needle exchange, by month and gender, 2016 
Source: Unpublished data from HSE, 2017  
 
 
MQI needle exchange 
As previously discussed, MQI is a national voluntary agency providing services for homeless people 
and for drug users. Its needle exchange and health promotion service provides drug users with 
information about the risks associated with drug use and the means to minimise such risks. It also 
provides drug users with a pathway into treatment and the possibility of living life without drugs 
(Merchants Quay Ireland 2016). The number of needle exchange interventions provided by the unit 
between 2011 and 2015 is shown in Figure 1.5.3.5. 
 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Total 1369 1326 1518 1519 1674 1639 1758 1780 1764 1701 1531 1668
Unique males 1107 1090 1220 1268 1374 1343 1441 1476 1452 1413 1255 1346
Unique females 261 236 298 286 299 296 317 305 312 288 276 322
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Total 1547 1512 1486 1511 1568 1640 1629 1769 1814 1616 1639 1646
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Figure 1.5.3.5 Number of needle exchange interventions, MQI Health Promotion Unit, 2011–2015 
Source: MQI, 2016 
 
In 2015, there were 27,388 visits to MQI’s Drug Services, and increase of 4% on the number of 
visits in 2014, and there were 25,745 needle exchange interventions, an increase of 6% on the 
number of interventions in 2014. A total of 2,676 individuals used the service, of which 461 were 
new clients. 
 
MQI, in association with the MRDTF and the HSE, administers the Midlands Family Support and the 
Community Harm Reduction services, providing outreach and working with families of those actively 
using drugs in this task force region. The services facilitated an average of 164 needle exchanges 
each month and operated in close partnership with local pharmacy-based needle exchange 
schemes. 
 
1.5.4 Harm reduction services: availability and access 
Alcohol treatment services in Ireland: How the public views them 
The HSE has recently published findings from a study that examined the level of public support in 
Ireland for alcohol screening in healthcare settings, and that assessed if alcohol treatment services 
are deemed available and adequate (Hope and Barry 2016). The study was based on two cross-
sectional national drinking surveys conducted in 2006 and 2010. For the purpose of this research, 
the two survey data sets were combined (n=2011) to allow for detailed analysis.  
 
A similar methodology was used across the two surveys: that of a national quota sample of adults 
aged 18 years and over using face-to-face interviews. The response rate was 62%. Several main 
findings from the study are discussed below. 
 
Alcohol screening in healthcare settings 
A majority of survey respondents agreed that intervention by health professionals regarding 
patients’ drinking habits in different healthcare settings should take place. The highest level of 
support for asking patients about their drinking behaviours as standard practice was in maternity 
services (91%), followed by general hospitals (84%) and primary care (80%). 
 
Demographics 
A higher percentage of married people (82%) in comparison to single people (77%) agreed that GPs 
should ask all patients about their drinking habits as standard practice. Across the regions of 
Ireland, those living in Dublin were less supportive of GP intervention in comparison to the rest of 
Leinster (79% vs 87%). More women than men (86% vs 82%) were supportive of alcohol screening; 
respondents who were younger were less supportive. Support was higher among those from lower 
socioeconomic classes (87%) in comparison to other classes.  
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Drinking patterns and alcohol harms 
Participants who abstained from alcohol were more supportive of health professionals asking 
patients about their drinking behaviours as standard practice. Respondents who were heavy 
drinkers were less supportive of alcohol screening in primary care, general hospitals and maternity 
services. Those who reported one or more of seven negative consequences due to their own 
drinking were also less supportive of alcohol screening by health professionals in general hospitals 
and in maternity services. Nevertheless, even among heavy drinkers, the majority (70%‒86%) were 
in favour of health practitioners asking about drinking habits. 
 
Availability and adequacy of alcohol treatment services 
Just 4 in 10 respondents agreed that alcohol treatment services were available in their local health 
service area, whereas a similar number (43%) were unaware (don’t know) if alcohol treatment 
services were available. In addition, only one in five agreed that alcohol treatment services were 
adequate, whereas one in four believed that treatment services were not adequate and over half 
were unsure (Figure 1.5.4.1). Subjects who lived in Dublin were significantly (p<0.01) less aware of 
the availability of alcohol treatment services in their local health service area when compared to 
respondents from other regions, with two-thirds saying they did not know if treatment services were 
available. 
 
 
Figure 1.5.4.1 Alcohol treatment in Ireland – perceived availability and adequacy of services 
Source: HSE, 2016 
 
Conclusions 
The results from these surveys suggest that most Irish adults are supportive of alcohol screening in 
healthcare settings. However, the findings also indicate that a high percentage of survey 
respondents were unaware of the availability of alcohol treatment services in local health areas. The 
authors suggest that these findings will be relevant in the planning of future services in relation to 
alcohol and other substance use. Effective delivery of alcohol screening, as well as early 
intervention, may help reduce the burden and associated cost of alcohol-related problems in Ireland. 
 
Availability of and access to harm reduction services for drug users 
See section 1.5.3 for information on the availability of and access to harm reduction services for 
drug users in Ireland. For information on the availability of and access to harm reduction services 
within Irish prisons, see Prison workbook Section 1.3.3. 
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2. New developments 
2.1 New developments in drug-related infectious diseases 
No effect of recent or former injecting drug use on HCV treatment adherence or therapeutic 
response – results from a large HCV treatment programme in Ireland 
 
Background 
PWID represent the majority of the HCV epidemic in the developed world (Nelson, et al. 2011). The 
majority of new infections develop in active PWID, with this group accounting for more than 80% of 
new infections in high-income countries (Cornberg, et al. 2011). Furthermore, an additional large 
reservoir of infection exists amongst former PWID who remain undiagnosed. 
 
Historically, HCV treatment guidelines have excluded PWID from consideration for treatment. Drug 
injectors are viewed as having ‘difficult to treat’ HCV, with perceived inferior treatment adherence 
and outcomes, as well as concerns regarding re-infection risk. Important factors that have limited 
treatment uptake in PWID are the contraindications and adverse effects of Interferon-based (IFN-
based) therapy. The development and availability of IFN-free direct-acting antiviral (DAA) regimes 
with high efficacy, improved tolerability and a limited side effect profile will significantly increase the 
proportion of patients who can be offered HCV therapy. However, adherence to therapy in ‘real-
world’ population groups will remain paramount in the DAA era. A recent study conducted in Ireland 
investigated differences in HCV treatment adherence and outcomes between former PWID, recent 
PWID and non-drug users treated with IFN and ribavirin therapy (Elsherif, et al. 2017). In this study, 
which has been published in the journal PLOS ONE, differences between PWID and non-drug users 
were analysed for adherence to treatment and outcomes in all patients treated for chronic HCV 
infection in a university teaching hospital in Ireland from 2002 to 2012. The PWID group also 
included former and recent drug users who were treated in a community-based drug treatment 
centre.  
 
Results  
Treatment completion/compliance 
There were 608 former PWID, 85 recent PWID and 307 non-PWID who commenced HCV therapy. 
There was no significant difference in treatment non-completion (for reasons other than virologic 
non-response) between PWID and non-PWID (8.4% vs 6.8%; relative risk: 1.23, 95% CI: 0.76–
1.99). Additionally, there was no significant difference in treatment non-completion between former 
and recent PWID (8.7% vs 5.9%; relative risk: 0.84, 95% CI: 0.33–2.10). Fifteen patients (17.6%) in 
the recent PWID group tested positive for opiates at least once during treatment, 11 (12.9%) tested 
positive for benzodiazepines and five (5.9%) tested positive for cocaine. Seven patients tested 
positive for two of the drug classes, while five tested positive for all three classes. No patients 
reported injecting illicit drugs during treatment or in the six-month post-treatment follow-up period. 
 
Response to treatment 
As shown in Figure 3.2.1, the overall sustained virologic response (SVR) rate in PWID (64.1%) was 
not significantly different from non-PWID (60.9%) (relative risk: 1.05, 95% CI: 0.95–1.17). In 
addition, there was no significant difference in SVR rates between the groups when comparing 
genotype 1 and genotype 3 infections. 
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Figure 2.1.1. Treatment response: Rates of sustained virologic response (95% CI bars) with dual therapy in PWID 
(people who inject drugs) and non-PWID (a) for all genotypes: 64.1% vs 60.9% (b) genotype 1: 48.6% vs 48.6% and 
(c) genotype 3: 74.7% vs 73.3% 
Source: Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, et al., 2017 
 
Follow-up data on 219 former PWID who achieved SVR between 2002 and 2007 for a median of 57 
months (ranging from six to 168 months) indicated that 13 patients were re-infected with HCV, a re-
infection rate of 10.5 per 1,000 person years of follow-up. All 13 of the re-infected patients had a 
relapse in injecting drug use. There was no significant difference in re-infection rates between 
former PWID with and without HIV co-infection. 
 
Conclusions 
The results from this large retrospective study of a decade of HCV treatment outcomes in Ireland 
indicate that PWID have similar treatment adherence to IFN and DAA HCV therapy as non-PWID 
patients with chronic HCV infection. In addition, PWID patients have a comparable response to 
treatment. The authors conclude that prioritising PWID for HCV treatment may be a cost-effective 
initiative for reducing long-term health costs, and that HCV elimination is an ambitious target that 
cannot be achieved by excluding PWID from treatment. 
 
2.2 New developments in harm reduction interventions 
On 17 July 2017, the Irish Taoiseach, Leo Varadkar, joined the Minister for Health Simon Harris and 
Minister of State Catherine Byrne to launch Reducing Harm, Supporting Recovery: A health-led 
response to drug and alcohol use in Ireland 2017–2025 (Department of Health 2017). Reducing 
Harm, Supporting Recovery lays out the direction of Government policy on drug and alcohol use 
until 2025. The new strategy aims to provide an integrated public health approach to drug and 
alcohol use, focused on promoting healthier lifestyles within society.  
 
The strategy contains an ambitious 50-point action plan from 2017 to 2020, and provides the scope 
to develop further actions between 2021 and 2025 to ensure the continued relevance of the strategy 
to emerging needs in the future. The vision of the strategy is to create a healthier and safer Ireland, 
and its actions will contribute to improving the health, well-being and safety of the population of 
Ireland in the coming years. Launching the strategy, the Taoiseach said, “For the ideal of a Republic 
of Opportunity to be meaningful, it must apply to all. Treating substance abuse and drug addiction 
as a public health issue, rather than a criminal justice issue, helps individuals, helps families, and 
helps communities. It reduces crime because it rebuilds lives. So it helps all of us.”  
 
Key actions of Reducing Harm, Supporting Recovery include the following:  
 
 Introduction of a pilot supervised injecting facility in Dublin’s city centre.  
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 Establishment of a Working Group to examine alternative approaches to the possession for 
personal use of small quantities of illegal drugs. 
 Funding for a programme to promote community awareness of alcohol-related harm. 
 A new targeted youth services scheme for young people at risk of substance misuse in 
socially and economically disadvantaged communities. 
 Expansion of drug and alcohol addiction services, including residential services. 
 Recruitment of four Clinical Nurse Specialists and two Young Persons Counsellors to 
complement HSE multidisciplinary teams for under-18s. 
 Recruitment of seven additional drug-liaison midwives to support pregnant women with 
alcohol dependency. 
 Establishment of a Working Group to explore ways of improving progression options for 
people exiting treatment, prison or community employment schemes, with a view to 
developing a new programme of supported care and employment.  
 
For further information on the Reducing Harm, Supporting Recovery drugs strategy see Policy 
workbook Section 1.1.1. 
3. Additional information 
3.1 Additional sources of information 
A typology of alcohol consumption among university students in Ireland 
Elevated levels of alcohol consumption among university students are well documented, with 
research indicating a rise in alcohol use among students in Ireland and increasing levels of high-risk 
drinking, which is often associated with illicit substances use (Davoren, et al. 2015). Policy-makers 
have attempted to combat this problem, as tailoring effective public health policy is crucial to 
tackling this burgeoning issue. Recently, typologies have been hypothesised as a pertinent public 
health tool. While traditional analysis methods tend to categorise individuals based on consumption 
profile alone, a typology approach may enhance an understanding of a societal phenomenon while 
making it possible to note patterns. 
 
Recent research conducted by University College Cork aimed to develop a typology of alcohol 
consumption among the Irish university student population (Davoren, et al. 2016). In this study, 
published in the journal BMJ Open, hundreds of possible statements on types of alcohol 
consumption were generated from a systematic review and a set of one-on-one interviews. These 
were then reduced to 36 statements. Forty-three students were advised to scan through the 36 
statements and fill the statements into a ‘forced choice, standardised distribution’. Following this, a 
45–90-minute interview was conducted with each student to illuminate subjectivity surrounding 
alcohol consumption. 
 
A typology describing four distinct groupings of alcohol consumer was uncovered. These were: 
 
 ‘Guarded drinker, careful spender, controlled enjoyment’: Characterised by students 
who enjoy socialising but only within the remit of social, family or cultural rules, which are 
self-regulated, and who described their alcohol consumption as cautious and light. 
 ‘Calculated hedonists’: Students who indicated a hedonistic style of drinking. These 
students drank alcohol to feel pleasure, to enjoy themselves, to have fun and to become 
drunk. 
 ‘Peer influenced with an ulterior motive’: Students who focused on consuming alcohol as 
part of a group or at a party. These individuals were motivated by the sense of belonging 
they gain from alcohol consumption, indicating that drinking helps them to feel a part of the 
group and adds a sense of social confidence. 
 ‘Inevitable bingers’: Students who described how they drink until all the alcohol they have 
is gone. These individuals noted self-inflicted dangerous situations arising from their own 
behaviours and drinking habits.  
 
As this was the ﬁrst study to propose types of alcohol consumption based on a student’s own 
subjectivity, the authors acknowledge that future research will be required to investigate the degree 
41 
 
to which each of these types is subscribed. Nevertheless, these proﬁles may provide a framework 
for public policy-makers and health promotion practitioners when tackling substance use at both a 
micro and macro level. 
 
4. Sources and methodology 
4.1 Sources 
Data for this workbook were provided using five sources: 
 
 National Drug-Related Deaths Index (NDRDI) 
 Health Protection Surveillance Centre (HPSC) 
 Hospital In-Patient Enquiry (HIPE) scheme 
 National Psychiatric In-patient Reporting System (NPIRS) 
 National Self-Harm Registry Ireland 
 
4.2 Methodology 
Established in 2005, the National Drug-Related Deaths Index (NDRDI), which is maintained by 
the HRB, is an epidemiological database that records cases of death by drugs poisoning, and 
deaths among drug users in Ireland, extending back to 1998. The NDRDI also records data on 
alcohol-related poisoning deaths and deaths among those who are alcohol dependent, extending 
back to 2004.  
 
The Health Protection Surveillance Centre (HPSC) is Ireland’s specialist agency for the 
surveillance of communicable diseases. Part of the HSE, and originally known as the National 
Disease Surveillance Centre, the HPSC endeavours to protect and improve the health of the Irish 
population by collating, interpreting and disseminating data to provide the best possible information 
on infectious disease. The HPSC has recorded new cases among injecting drug users of HIV since 
1982, HBV since 2004 and HCV since 2006.  
 
The Hospital In-Patient Enquiry (HIPE) scheme is a computer-based health information system 
managed by the Economic and Social Research Institute (ESRI) in association with the Department 
of Health and the HSE. It collects demographic, medical and administrative data on all admissions, 
discharges and deaths from acute general hospitals in Ireland. It was started on a pilot basis in 1969 
and then expanded and developed as a national database of coded discharge summaries from the 
1970s onwards. Each HIPE discharge record represents one episode of care; each discharge of a 
patient, whether from the same or a different hospital and with the same or a different diagnosis, 
gives rise to a separate HIPE record. The scheme, therefore, facilitates analysis of hospital activity 
rather than of the incidence of disease. HIPE does not record information on individuals who attend 
accident and emergency units but are not admitted as inpatients. 
 
The National Psychiatric In-patient Reporting System (NPIRS), administered by the HRB, is a 
national psychiatric database that provides detailed information on all admissions to, and discharges 
from, 56 inpatient psychiatric services in Ireland. It records data on cases receiving inpatient 
treatment for problem drug and alcohol use. NPIRS does not collect data on the prevalence of 
psychiatric co-morbidity in Ireland. The HRB publishes an annual report on the data collected by the 
NPIRS, entitled Activities of Irish Psychiatric Units and Hospitals.  
 
The National Self-Harm Registry Ireland is a national system of population monitoring for the 
occurrence of deliberate self-harm, established by the National Suicide Research Foundation at the 
request of the Department of Health and Children. Since 2006–2007, the Registry has achieved 
complete national coverage of hospital-treated deliberate self-harm. The Registry defines deliberate 
self-harm as ‘an act with a non-fatal outcome in which an individual deliberately initiates a non-
habitual behaviour that, without intervention from others, will cause self-harm, or deliberately ingests 
a substance in excess of the prescribed or generally recognised therapeutic dosage, and which is 
aimed at realising changes that the person desires via the actual or expected physical 
consequences’. All methods of deliberate self-harm are recorded in the Registry, including drug 
overdoses and alcohol overdoses, where it is clear that the self-harm was intentionally inflicted. All 
individuals who are alive on admission to hospital following a deliberate act of self-harm are 
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included. Not considered deliberate self-harm are accidental overdoses – e.g., an individual who 
takes additional medication in the case of illness, without any intention to self-harm; alcohol 
overdoses alone, where the intention was not to self-harm; or accidental overdoses of street drugs 
(drugs used for recreational purposes), without the intention to self-harm – and individuals who are 
dead on arrival at hospital as a result of suicide.   
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European Monitoring Centre for Drugs and Drug Addiction 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a decentralised EU 
agency based in Lisbon.  The EMCDDA provides the EU and its Member States with information on 
the nature, extent, consequences and responses to illicit drug use. It supplies the evidence base to 
support policy formation on drugs and addiction in both the European Union and Member States.   
There are 30  National Focal Points that act as monitoring centres for the EMCDDA.  These focal 
points gather and analyse country data according to common data-collection standards and tools 
and supply these data to the EMCDDA. The results of this national monitoring process are supplied 
to the Centre for analysis, from which it produces the annual European drug report and other 
outputs. 
 
The Irish Focal Point to the EMCDDA is based in the Health Research Board.  The focal point 
writes and submits a series of textual reports, data on the five epidemiological indicators and supply 
indicators in the form of standard tables and structured questionnaires on response-related issues 
such as prevention and social reintegration.  The focal point is also responsible for implementing 
Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances. 
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